Hypercalcemia Clinical Trials

Find Hypercalcemia Clinical Trials Near You

Evaluation of the Role of Luteinizing Hormone (LH) and Human Chorionic Gonadotropin (hCG) in Adult Patients Undergoing Assessment for Endocrine Disorders

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Hormones are chemical messengers that help regulate many functions in the body. As women go through menopause, and as men age, levels of certain reproductive hormones change significantly. One of these hormones, luteinizing hormone (LH), increases substantially after menopause and may also rise in some men. Another hormone, human chorionic gonadotropin (hCG), is best known as the hormone of pregnancy, but small amounts can also be detected in some postmenopausal women and older men. Recent research suggests that LH and hCG may have effects beyond reproduction. These hormones may influence bone health, body weight, kidney function, thyroid function, and adrenal gland function. However, little is known about their importance in patients with endocrine disorders. The purpose of this study is to investigate whether blood levels of LH and hCG are associated with the presence, severity, and long-term outcomes of endocrine diseases. The study will include adult patients undergoing evaluation for hormonal disorders. Blood samples will be analyzed for LH, hCG, and other relevant hormones and biomarkers. Participants will also be followed through national health registries to examine whether these hormone levels are associated with future health outcomes. The results of this study may improve our understanding of how LH and hCG affect the body and help determine whether these hormones can be used as biomarkers to improve the diagnosis and management of endocrine diseases.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:

• Patients referred to or patients actively followed at the Department of Endocrinology and Internal Medicine at Herlev Hospital

• Age 18-90

Locations
Other Locations
Denmark
Department of Endocrinology and Internal Medicine, Herlev Hospital
RECRUITING
Herlev
Contact Information
Primary
Martin B Jensen, Professor
martin.blomberg.jensen@regionh.dk
+4538687318
Backup
Mads J Jorsal, MD
mads.joon.jorsal@regionh.dk
Time Frame
Start Date: 2026-01-01
Estimated Completion Date: 2045-12
Participants
Target number of participants: 20000
Treatments
Patients with presumed osteoporosis
Patients with presumed Hypercalcemia / Primary Hyperparathyroidism
Patients with presumed thyroidal illness
Patients with presumed adrenal disease
Patients with presumed pituitary disease
Sponsors
Leads: Martin Blomberg Jensen
Collaborators: Copenhagen University Hospital at Herlev

This content was sourced from clinicaltrials.gov